Subtype
Cervical Neoplasm
CI-CAN-00004801Explore in graph →
Non-malignant573 active trials4 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004801Explore in graph →
Clinical trials
2,386 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05990803 | A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies | recruiting | Phase 2 | 130 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 |
| clinicaltrials |
| NCT07088731 | Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 180 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07177716 | Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07172217 | The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC | not yet recruiting | Phase 2 | 33 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07055399 | Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)(NICE-CC) | recruiting | Phase 2 | 43 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05462379 | Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment. | active not recruiting | Phase 1 / Phase 2 | 22 | MARILIA ALBANEZI BERTOLAZZIOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07153952 | RT for Adenocarcinoma/Adenosquamous Carcinoma | active not recruiting | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07141186 | QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy | not yet recruiting | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT07130240 | Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 and IIA1 Cervical Cancer | recruiting | Phase 2 | 20 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07104149 | Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer | recruiting | Phase 2 | 29 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07095478 | Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer(NeoART-CIN) | not yet recruiting | Phase 2 | 28 | Metanoic Health Ltd.INDUSTRY | 1 | Jul 31, 2025 | clinicaltrials |
| NCT07092696 | Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer | recruiting | Phase 2 | 34 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07003620 | Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial | recruiting | Phase 2 | 34 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 150 | Cancer Research UKOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06998394 | A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer | recruiting | Phase 2 | 30 | Xiangbo WanOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT03101995 | Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease | recruiting | Phase 2 | 18 | National Institute of CancerologíaOTHER_GOV | 1 | May 28, 2025 | clinicaltrials |
| NCT06986057 | Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer | not yet recruiting | Phase 2 | 28 | Shandong Tumor HospitalOTHER | 0 | May 22, 2025 | clinicaltrials |
| NCT06981858 | A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 34 | Chongqing University Cancer HospitalOTHER | 0 | May 21, 2025 | clinicaltrials |
| NCT06942416 | Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer | recruiting | Phase 2 | 36 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT06916117 | Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC | not yet recruiting | Phase 2 | 30 | RenJi HospitalOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06878222 | Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC | recruiting | Phase 2 | 35 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06882447 | A Study of QL1706 Combined with Nine HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer(QL1706) | not yet recruiting | Phase 2 | 35 | Northern Jiangsu People's HospitalOTHER | 0 | Mar 28, 2025 | clinicaltrials |
| NCT06786780 | Establishment and Validation of Prediction Model of Simultaneous Chemoradiotherapy for Cervical Cancer Organoids(ECCO) | enrolling by invitation | Phase 2 | 50 | Chongqing University Cancer HospitalOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04516616 | Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer | active not recruiting | Phase 2 | 85 | Huazhong University of Science and TechnologyOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06288360 | Neoadjuvant Immunochemotherapy in PD-L1-negative LACC | recruiting | Phase 2 | 40 | Tongji HospitalOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06093438 | Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer | recruiting | Phase 1 / Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT04487587 | A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer(COMICE) | active not recruiting | Phase 2 | 79 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06123884 | BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer | recruiting | Phase 2 / Phase 3 | 526 | Bio-Thera SolutionsINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | active not recruiting | Phase 2 | 170 | Xencor, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06805864 | Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma(BROTHER) | not yet recruiting | Phase 2 | 45 | Gunma UniversityOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT06800391 | Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients(REVERSE) | recruiting | Phase 2 | 31 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06630611 | Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)(PragmaTIL) | recruiting | Phase 2 | 40 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06783153 | Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06771596 | Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix(CC11) | active not recruiting | Phase 2 | 43 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06755515 | A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | enrolling by invitation | Phase 2 / Phase 3 | 510 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06745219 | Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer | not yet recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06724263 | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | not yet recruiting | Phase 2 | 120 | Tasly Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06278857 | SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)(SATELLITE) | recruiting | Phase 2 | 10 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06705322 | Cnidium Monnieri Detoxification Formula for Persistent High-risk Human Papillomavirus Infection of Cervix. | not yet recruiting | Phase 2 | 79 | Fudan UniversityOTHER | 0 | Nov 26, 2024 | clinicaltrials |
| NCT02387203 | Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin | active not recruiting | Phase 2 | 80 | Mercy Medical CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06686043 | HPV Vaccine, Imiquimod, and Metformin Combination Trial(HPV-VIM) | recruiting | Phase 2 | 85 | Baylor College of MedicineOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT06681636 | Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure(HPV9vxFSW) | not yet recruiting | Phase 2 | 300 | National Institute of Hygiene and Epidemiology, VietnamOTHER | 2 | Nov 8, 2024 | clinicaltrials |
| NCT06289062 | Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer | recruiting | Phase 2 | 40 | Tongji HospitalOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06672653 | Tolerance and Effectiveness of C14 on HPV Infection(PREPAP) | not yet recruiting | Phase 1 / Phase 2 | 66 | MGB PharmaINDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06288373 | Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC | recruiting | Phase 2 / Phase 3 | 440 | Tongji HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Sep 26, 2025source: clinicaltrials